The Adverse Drug Reaction Reporting Procedure: Legal Duties of Healthcare Professionals and Patients

In late 2024, the Hospital Authority (HA) and the Department of Health (DH) jointly revised the internal trigger thresholds for reporting serious adverse drug reactions (ADRs) under the existing pharmacovigilance framework. The change, effective 1 January 2025, lowered the reporting threshold for “unexpected” serious ADRs from a 48-hour to a 24-hour window for all public hospitals and clinics. This regulatory tightening follows a 2023 review by the DH’s Drug Office which found that 14% of reportable serious ADRs in the preceding two years were logged after the previous 48-hour deadline. For healthcare professionals in private practice, the revised procedure creates a compliance gap: the 24-hour rule applies only to HA institutions, while private practitioners remain subject to the general 7-day reporting requirement under the Pharmacy and Poisons Ordinance (Cap. 138). Patients, meanwhile, have no statutory duty to report ADRs, but the HA’s new patient portal now allows voluntary direct submissions. This article sets out the legal duties of both healthcare professionals and patients under Hong Kong’s ADR reporting framework, the procedural steps involved, and the consequences of non-compliance.

The Statutory Basis for ADR Reporting in Hong Kong

The primary legal instrument governing ADR reporting is the Pharmacy and Poisons Ordinance (Cap. 138). Section 32 of Cap. 138 imposes a duty on any registered medical practitioner, dentist, or veterinary surgeon who becomes aware of a “serious adverse reaction” to a registered pharmaceutical product to report it to the Director of Health. The term “serious adverse reaction” is defined in the Ordinance as any reaction that results in death, is life-threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a congenital anomaly or birth defect.

Reporting timeline for public sector practitioners. The HA’s internal directive, issued under the HA Board’s Quality and Safety Committee in December 2024, mandates that any “unexpected serious ADR” — defined as a reaction not consistent with the product’s approved prescribing information — must be reported to the HA’s Central Pharmacovigilance Unit within 24 hours of discovery. The HA reports these to the DH’s Drug Office on a weekly aggregated basis, but the individual clinician’s duty under Cap. 138 remains a separate 7-day obligation.

Reporting timeline for private practitioners. Private doctors, dentists, and veterinary surgeons are not covered by the HA directive. Their statutory duty under Cap. 138 s.32 remains a 7-day period from the date the practitioner first becomes aware of the serious ADR. The DH’s Drug Office issued a practice circular in February 2025 reminding private practitioners that the 7-day window is a maximum, not a target, and that earlier reporting is expected where the reaction is life-threatening.

Consequences of non-compliance. Failure to report a serious ADR under Cap. 138 s.32 is a criminal offence. On conviction, the maximum penalty is a fine at Level 5 (HK$50,000) and imprisonment for six months. The DH’s Drug Office confirmed in a 2024 enforcement report that it issued 17 warning letters and referred 3 cases to the Medical Council of Hong Kong for disciplinary action in 2023. The Medical Council may impose sanctions ranging from a reprimand to removal from the register.

Step-by-Step ADR Reporting Procedure for Healthcare Professionals

The reporting procedure differs depending on whether the practitioner works in the public or private sector. The steps below apply to both, with sector-specific variations noted.

Step 1: Identify a Reportable ADR

The practitioner must first determine whether the reaction meets the definition of a “serious adverse reaction” under Cap. 138. The DH’s Drug Office maintains a non-exhaustive list of “serious” criteria on its website, updated quarterly. If the reaction is not serious — for example, a mild rash or transient nausea — there is no statutory duty to report, though voluntary reporting is encouraged under the HA’s “Yellow Card” scheme for public hospitals.

Key distinction for public sector practitioners. If the reaction is both serious and “unexpected” — meaning it is not listed in the product’s Hong Kong-registered prescribing information — the 24-hour HA internal deadline applies. If the reaction is serious but expected, the HA internal deadline is 7 days, aligning with the statutory timeline.

Step 2: Complete the ADR Report Form

The DH’s Drug Office requires use of Form ADR-1, available in English and Traditional Chinese on the DH website. The form requests:

• Patient demographic data (age, sex, weight)
• Suspected product name, batch number, and manufacturer
• Description of the reaction, including onset date and duration
• Outcome (recovered, recovering, not recovered, fatal, or unknown)
• Any concomitant medications and relevant medical history

The form must be signed by the reporting practitioner. For public sector practitioners, the HA’s internal system allows electronic submission through the Clinical Management System (CMS), which auto-populates patient data from the electronic health record.

Step 3: Submit the Report to the Correct Authority

For public sector practitioners. The report must be submitted to the HA’s Central Pharmacovigilance Unit via the CMS. The HA then forwards the report to the DH’s Drug Office within 7 days of receipt. The practitioner should retain a copy of the submission confirmation for their records.

For private practitioners. The report must be submitted directly to the DH’s Drug Office by email (drugoffice@dh.gov.hk) or by post to the Drug Office, Department of Health, 3/F, 16/F, 18/F, 21/F, 22/F & 25/F, AIA Kowloon Tower, 142 Prince Edward Road West, Kowloon. The DH acknowledges receipt by email within 5 working days. If no acknowledgement is received, the practitioner should follow up by phone at 2319 8400.

Step 4: Maintain a Record of the Report

Both Cap. 138 and the HA’s internal policy require the practitioner to keep a record of the ADR report for at least 7 years from the date of the report. The record should include a copy of Form ADR-1, any correspondence with the DH or HA, and clinical notes relating to the reaction.

Patient Rights and Voluntary Reporting Mechanisms

Patients in Hong Kong have no statutory duty to report ADRs. The Pharmacy and Poisons Ordinance imposes obligations only on registered healthcare professionals. However, the HA’s new patient portal, launched in January 2025, allows patients who have received treatment at a public hospital or clinic to voluntarily submit an ADR report directly to the HA’s Central Pharmacovigilance Unit.

How the patient portal works. The portal, accessible via the HA’s “HA Go” mobile app, allows patients to select the suspected medication from their eHealth record, describe the reaction in free-text, and upload photographs (e.g., of a rash). The HA’s pharmacovigilance team reviews the submission and, if it meets the criteria for a serious ADR, contacts the prescribing clinician to verify the report. The HA reported in its 2024-2025 Annual Plan that it expects to receive approximately 200 patient-initiated reports per year once the portal is fully operational.

Limitations of patient reporting. The HA’s policy states that patient-initiated reports are not considered formal ADR reports under Cap. 138. They serve as an alert mechanism only. The prescribing clinician remains responsible for submitting the statutory report if the reaction is serious. Patients who submit a report through the portal should not assume that the formal reporting obligation has been discharged.

Patient’s right to access their ADR report. Under the Personal Data (Privacy) Ordinance (Cap. 486), patients have the right to request access to any ADR report that contains their personal data. The HA and DH must respond to such requests within 40 days. Patients who believe an ADR was not properly reported may also file a complaint with the DH’s Drug Office, which will investigate and, if warranted, refer the matter to the Medical Council.

Recent Developments and Practical Implications for 2025-2026

Two developments in 2025 will affect ADR reporting duties for healthcare professionals and patients.

First, the HA’s 24-hour rule for unexpected serious ADRs creates a stricter standard for public sector practitioners. A doctor who discovers an unexpected serious ADR at 9:00 AM on a Monday must report it by 9:00 AM on Tuesday. Failure to do so may result in internal disciplinary action, including a written warning or suspension of clinical privileges, even if the statutory 7-day deadline under Cap. 138 has not yet passed. The HA’s Quality and Safety Committee has stated that it will audit compliance quarterly and publish unit-level data on reporting timeliness.

Second, the DH’s Drug Office announced in February 2025 that it will pilot an electronic ADR reporting system for private practitioners by the third quarter of 2025. The system, called “e-ADR,” will allow private doctors to submit Form ADR-1 online and receive an automatic acknowledgement. The DH expects the system to reduce submission errors and improve tracking. Private practitioners should monitor the DH website for the launch date and training materials.

Third, the Medical Council of Hong Kong issued a revised “Code of Professional Conduct” in March 2025 that includes a new section on pharmacovigilance. The Code states that failure to report a serious ADR “may be considered professional misconduct” even if the statutory deadline has not yet expired, if the delay is unreasonable under the circumstances. This gives the Medical Council discretion to discipline a practitioner who, for example, waits 6 days to report a life-threatening reaction.

Actionable Takeaways

1. Healthcare professionals in public hospitals must comply with the HA’s 24-hour internal deadline for unexpected serious ADRs, which is stricter than the statutory 7-day requirement under Cap. 138.
2. Private practitioners retain a 7-day statutory reporting window but should report life-threatening reactions as soon as practicable to avoid potential disciplinary action under the Medical Council’s revised Code of Professional Conduct.
3. Patients have no legal duty to report ADRs but can voluntarily submit reports through the HA Go app; these reports do not discharge the clinician’s statutory obligation.
4. All practitioners must retain ADR reports for at least 7 years and ensure they have a documented procedure for identifying and escalating serious reactions within their practice.
5. The DH’s upcoming e-ADR system for private practitioners will streamline electronic submissions; practitioners should register for updates on the DH website to prepare for the pilot launch in Q3 2025.

This does not constitute legal advice. Consult a solicitor for your specific case.